759 related articles for article (PubMed ID: 29896681)
1. Vaccine Development for Epstein-Barr Virus.
Cohen JI
Adv Exp Med Biol; 2018; 1045():477-493. PubMed ID: 29896681
[TBL] [Abstract][Full Text] [Related]
2. The need and challenges for development of an Epstein-Barr virus vaccine.
Cohen JI; Mocarski ES; Raab-Traub N; Corey L; Nabel GJ
Vaccine; 2013 Apr; 31 Suppl 2(0 2):B194-6. PubMed ID: 23598481
[TBL] [Abstract][Full Text] [Related]
3. The promise of a prophylactic Epstein-Barr virus vaccine.
Balfour HH; Schmeling DO; Grimm-Geris JM
Pediatr Res; 2020 Jan; 87(2):345-352. PubMed ID: 31641280
[TBL] [Abstract][Full Text] [Related]
4. Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults.
Sokal EM; Hoppenbrouwers K; Vandermeulen C; Moutschen M; Léonard P; Moreels A; Haumont M; Bollen A; Smets F; Denis M
J Infect Dis; 2007 Dec; 196(12):1749-53. PubMed ID: 18190254
[TBL] [Abstract][Full Text] [Related]
5. Predictors of Epstein-Barr virus serostatus and implications for vaccine policy: A systematic review of the literature.
Winter JR; Jackson C; Lewis JE; Taylor GS; Thomas OG; Stagg HR
J Glob Health; 2020 Jun; 10(1):010404. PubMed ID: 32257152
[TBL] [Abstract][Full Text] [Related]
6. Rabbits immunized with Epstein-Barr virus gH/gL or gB recombinant proteins elicit higher serum virus neutralizing activity than gp350.
Cui X; Cao Z; Chen Q; Arjunaraja S; Snow AL; Snapper CM
Vaccine; 2016 Jul; 34(34):4050-5. PubMed ID: 27291087
[TBL] [Abstract][Full Text] [Related]
7. The Development of Prophylactic and Therapeutic EBV Vaccines.
Smith C; Khanna R
Curr Top Microbiol Immunol; 2015; 391():455-73. PubMed ID: 26428385
[TBL] [Abstract][Full Text] [Related]
8. Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases.
Cui X; Snapper CM
Front Immunol; 2021; 12():734471. PubMed ID: 34691042
[TBL] [Abstract][Full Text] [Related]
9. Vaccine strategies against Epstein-Barr virus-associated diseases: lessons from studies on cytotoxic T-cell-mediated immune regulation.
Khanna R; Moss DJ; Burrows SR
Immunol Rev; 1999 Aug; 170():49-64. PubMed ID: 10566141
[TBL] [Abstract][Full Text] [Related]
10. Epstein-barr virus vaccines.
Cohen JI
Clin Transl Immunology; 2015 Jan; 4(1):e32. PubMed ID: 25671130
[TBL] [Abstract][Full Text] [Related]
11. Designing an effective vaccine to prevent Epstein-Barr virus-associated diseases: challenges and opportunities.
Dasari V; Bhatt KH; Smith C; Khanna R
Expert Rev Vaccines; 2017 Apr; 16(4):377-390. PubMed ID: 28276306
[TBL] [Abstract][Full Text] [Related]
12. High Epstein-Barr Virus Load and Genomic Diversity Are Associated with Generation of gp350-Specific Neutralizing Antibodies following Acute Infectious Mononucleosis.
Weiss ER; Alter G; Ogembo JG; Henderson JL; Tabak B; Bakiş Y; Somasundaran M; Garber M; Selin L; Luzuriaga K
J Virol; 2017 Jan; 91(1):. PubMed ID: 27733645
[TBL] [Abstract][Full Text] [Related]
13. Progress, prospects, and problems in Epstein-Barr virus vaccine development.
Balfour HH
Curr Opin Virol; 2014 Jun; 6():1-5. PubMed ID: 24632197
[TBL] [Abstract][Full Text] [Related]
14. Murine gamma-herpesvirus 68 glycoprotein 150 protects against virus-induced mononucleosis: a model system for gamma-herpesvirus vaccination.
Stewart JP; Micali N; Usherwood EJ; Bonina L; Nash AA
Vaccine; 1999 Jan; 17(2):152-7. PubMed ID: 9987149
[TBL] [Abstract][Full Text] [Related]
15. Immunization With Fc-Based Recombinant Epstein-Barr Virus gp350 Elicits Potent Neutralizing Humoral Immune Response in a BALB/c Mice Model.
Zhao B; Zhang X; Krummenacher C; Song S; Gao L; Zhang H; Xu M; Feng L; Feng Q; Zeng M; Xu Y; Zeng Y
Front Immunol; 2018; 9():932. PubMed ID: 29765376
[TBL] [Abstract][Full Text] [Related]
16. Epstein-Barr virus vaccine development: a lytic and latent protein cocktail.
Lockey TD; Zhan X; Surman S; Sample CE; Hurwitz JL
Front Biosci; 2008 May; 13():5916-27. PubMed ID: 18508632
[TBL] [Abstract][Full Text] [Related]
17. Sequence Variation of Epstein-Barr Virus: Viral Types, Geography, Codon Usage, and Diseases.
Correia S; Bridges R; Wegner F; Venturini C; Palser A; Middeldorp JM; Cohen JI; Lorenzetti MA; Bassano I; White RE; Kellam P; Breuer J; Farrell PJ
J Virol; 2018 Nov; 92(22):. PubMed ID: 30111570
[TBL] [Abstract][Full Text] [Related]
18. A novel vaccine candidate based on chimeric virus-like particle displaying multiple conserved epitope peptides induced neutralizing antibodies against EBV infection.
Zhang X; Zhao B; Ding M; Song S; Kang Y; Yu Y; Xu M; Xiang T; Gao L; Feng Q; Zhao Q; Zeng MS; Krummenacher C; Zeng YX
Theranostics; 2020; 10(13):5704-5718. PubMed ID: 32483413
[No Abstract] [Full Text] [Related]
19. Treatment of Epstein-Barr Virus infection in immunocompromised patients.
Pociupany M; Snoeck R; Dierickx D; Andrei G
Biochem Pharmacol; 2024 Jul; 225():116270. PubMed ID: 38734316
[TBL] [Abstract][Full Text] [Related]
20. Infectious mononucleosis and Epstein-Barr virus.
Vetsika EK; Callan M
Expert Rev Mol Med; 2004 Nov; 6(23):1-16. PubMed ID: 15541197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
